Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

46 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Circulating tumor DNA reveals complex biological features with clinical relevance in metastatic breast cancer.
Prat A, Brasó-Maristany F, Martínez-Sáez O, Sanfeliu E, Xia Y, Bellet M, Galván P, Martínez D, Pascual T, Marín-Aguilera M, Rodríguez A, Chic N, Adamo B, Paré L, Vidal M, Margelí M, Ballana E, Gómez-Rey M, Oliveira M, Felip E, Matito J, Sánchez-Bayona R, Suñol A, Saura C, Ciruelos E, Tolosa P, Muñoz M, González-Farré B, Villagrasa P, Parker JS, Perou CM, Vivancos A. Prat A, et al. Nat Commun. 2023 Mar 1;14(1):1157. doi: 10.1038/s41467-023-36801-9. Nat Commun. 2023. PMID: 36859416 Free PMC article.
SPARC mediates metastatic cooperation between CSC and non-CSC prostate cancer cell subpopulations.
Mateo F, Meca-Cortés O, Celià-Terrassa T, Fernández Y, Abasolo I, Sánchez-Cid L, Bermudo R, Sagasta A, Rodríguez-Carunchio L, Pons M, Cánovas V, Marín-Aguilera M, Mengual L, Alcaraz A, Schwartz S Jr, Mellado B, Aguilera KY, Brekken R, Fernández PL, Paciucci R, Thomson TM. Mateo F, et al. Mol Cancer. 2014 Oct 21;13:237. doi: 10.1186/1476-4598-13-237. Mol Cancer. 2014. PMID: 25331979 Free PMC article.
Safety, activity, and molecular heterogeneity following neoadjuvant non-pegylated liposomal doxorubicin, paclitaxel, trastuzumab, and pertuzumab in HER2-positive breast cancer (Opti-HER HEART): an open-label, single-group, multicenter, phase 2 trial.
Gavilá J, Oliveira M, Pascual T, Perez-Garcia J, Gonzàlez X, Canes J, Paré L, Calvo I, Ciruelos E, Muñoz M, Virizuela JA, Ruiz I, Andrés R, Perelló A, Martínez J, Morales S, Marín-Aguilera M, Martínez D, Quero JC, Llombart-Cussac A, Prat A. Gavilá J, et al. BMC Med. 2019 Jan 9;17(1):8. doi: 10.1186/s12916-018-1233-1. BMC Med. 2019. PMID: 30621698 Free PMC article. Clinical Trial.
Androgen Receptor and Its Splicing Variant 7 Expression in Peripheral Blood Mononuclear Cells and in Circulating Tumor Cells in Metastatic Castration-Resistant Prostate Cancer.
Marín-Aguilera M, Jiménez N, Reig Ò, Montalbo R, Verma AK, Castellano G, Mengual L, Victoria I, Pereira MV, Milà-Guasch M, García-Recio S, Benítez-Ribas D, Cabezón R, González A, Juan M, Prat A, Mellado B. Marín-Aguilera M, et al. Cells. 2020 Jan 14;9(1):203. doi: 10.3390/cells9010203. Cells. 2020. PMID: 31947623 Free PMC article.
Development and validation of the new HER2DX assay for predicting pathological response and survival outcome in early-stage HER2-positive breast cancer.
Prat A, Guarneri V, Pascual T, Brasó-Maristany F, Sanfeliu E, Paré L, Schettini F, Martínez D, Jares P, Griguolo G, Dieci MV, Cortés J, Llombart-Cussac A, Conte B, Marín-Aguilera M, Chic N, Puig-Butillé JA, Martínez A, Galván P, Tsai YH, González-Farré B, Mira A, Vivancos A, Villagrasa P, Parker JS, Conte P, Perou CM. Prat A, et al. EBioMedicine. 2022 Jan;75:103801. doi: 10.1016/j.ebiom.2021.103801. Epub 2022 Jan 3. EBioMedicine. 2022. PMID: 34990895 Free PMC article.
Transcriptional Profile Associated with Clinical Outcomes in Metastatic Hormone-Sensitive Prostate Cancer Treated with Androgen Deprivation and Docetaxel.
Jiménez N, Reig Ò, Marín-Aguilera M, Aversa C, Ferrer-Mileo L, Font A, Rodriguez-Vida A, Climent MÁ, Cros S, Chirivella I, Domenech M, Figols M, González-Billalabeitia E, Jiménez Peralta D, Rodríguez-Carunchio L, García-Esteve S, Garcia de Herreros M, Ribal MJ, Prat A, Mellado B. Jiménez N, et al. Cancers (Basel). 2022 Sep 29;14(19):4757. doi: 10.3390/cancers14194757. Cancers (Basel). 2022. PMID: 36230681 Free PMC article.
HER2DX genomic test in HER2-positive/hormone receptor-positive breast cancer treated with neoadjuvant trastuzumab and pertuzumab: A correlative analysis from the PerELISA trial.
Guarneri V, Bras-Maristany F, Dieci MV, Griguolo G, Par L, Mar Ín-Aguilera M, Miglietta F, Bottosso M, Giorgi CA, Blasco P, Castillo O, Galv N P, Vivancos A, Villagrasa P, Parker JS, Perou CM, Conte P, Prat A. Guarneri V, et al. EBioMedicine. 2022 Nov;85:104320. doi: 10.1016/j.ebiom.2022.104320. Epub 2022 Oct 29. EBioMedicine. 2022. PMID: 36374768 Free PMC article. Clinical Trial.
46 results